Newron Pharmaceuticals

181 articles with Newron Pharmaceuticals

• Zambon Announces Approval and ARTG Listing of Safinamide in Australia for Treatment of Patients with Parkinson’s Disease

  11/30/2018

  Further Regulatory Submissions Ongoing with Authorities Worldwide

• Newron Pharmaceuticals Hosts its 2018 R&D Day in New York City

  10/31/2018

  Leading clinicians presented new evidence on treatment options for patients suffering from Rett syndrome and treatment resistant schizophrenia

• Investment Plan for Europe: EIB Backs Italian CNS Drug Developer Newron Pharmaceuticals with up to EUR 40m

  10/30/2018

  The European Investment Bank (EIB) and Newron Pharmaceuticals S.p.A. signed a financing agreement today, which will allow the Company to borrow up to EUR 40 million over the coming years, subject to achieving a set of agreed performance criteria.

• Newron Pharmaceuticals to Webcast Presentations from 2018 R&D Day Event on October 31

  10/25/2018

  The company will live video webcast the event beginning 10:00 AM EDT

• Newron Pharmaceuticals Announces Prominent Medical Experts to Present at its 2018 R&D Day on October 31 in New York

  10/15/2018

  Leading clinicians in the fields of schizophrenia and Rett syndrome, John Kane, MD and Daniel Glaze, MD to present at research and investor update event

• Newron Dedicates Efforts to Research and Advocacy During Rett Awareness Month in October

  10/8/2018

  Families come together to share patient experience and treatment needs at an international conference in Rome, Italy

• Newron Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference in New York

  9/25/2018

  Newron is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.

• Newron Pharmaceuticals to Host 2018 R&D Day on October 31 in New York City – Save the Date

  9/12/2018

  Newron Pharmaceuticals S.p.A. today announced that its 2018 R&D Day will be held in New York City on October 31, 2018, from 10:00AM to 1:00PM EDT.

• Newron Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference

  8/1/2018

  Newron Pharmaceuticals S.p.A. announced that Stefan Weber, CEO, will present at the Wedbush PacGrow Healthcare Conference in New York, NY, on Wednesday, August 15, 2018 at 1:20 p.m. ET.

• Newron Provides Update on STARS Clinical Study with Sarizotan for the Treatment of Rett Syndrome

  6/13/2018

  Newron Pharmaceuticals S.p.A. announces that the STARS clinical study (Sarizotan Treatment of Apneas in Rett Syndrome) in patients with Rett syndrome is expected to complete enrollment in H2 2018.

• Newron Pharmaceuticals Announces Shareholders Accepted All Motions at the AGM 2018

  3/27/2018

  About 24.9% of Newron’s total capital of 17,844,345 shares were represented at the meeting.

• Newron Announces 2017 Financial Results and Provides Outlook for 2018

  3/1/2018

  Newron Pharmaceuticals S.p.A. announces its financial results and operational highlights for the year ended December 31, 2017, and provides an outlook for 2018. Additionally, Newron announces the approved agenda for the Company’s 2018 shareholders’ meeting.

• Newron Supports Global Rare Disease Day 2018 and Rett Syndrome Studies

  2/13/2018

  Observed on February 28, Rare Disease Day helps raise awareness of rare diseases, and in turn improve access to treatments.

• Newron Pharmaceuticals S.p.A. Announces Change in the Board of Directors

  2/9/2018

  Newron today announced that Bo Jesper Hansen has informed the Board of Directors of his intention to step down as a Non-Executive Director, effective from this year’s Annual Shareholders Assembly taking place on March 27, 2018.

• Newron Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York

  2/6/2018

  Newron announced that Stefan Weber, CEO, will present at the 20th Annual BIO CEO & Investor Conference in New York, NY on Monday, Feb. 12, 2018 at 10:15 a.m. ET in the Wilder Room at the New York Marriott Marquis.

• Newron Provides End of Year Corporate Update

  12/11/2017

  Significant progress has been made in 2017 with the approval and launch of Xadago for the treatment of patients with Parkinson’s disease (PD) in the U.S. in July, and its commercialization in 12 European countries.

• Newron Pharmaceuticals Announces Advisory Board Recommendations and Rett Congress Findings

  11/7/2017

  At the Rett Congress, Newron’s Burden of Disease advisory board reached a consensus on the concept elicitation interviews which are being used to develop a survey that will be distributed internationally to caregivers and allied healthcare professionals.

• Newron Pharmaceuticals to Present at European Rett Syndrome Congress and Host Advisory Board Meeting

  10/25/2017

  Newron Pharmaceuticals S.p.A. today announced an oral presentation at the upcoming European Rett Syndrome Congress (“the congress”) in Berlin, Germany, November 2-4, 2017.

• Newron Pharma Supports Rett Syndrome Awareness Month This October

  10/6/2017

• Newron Pharma Reports Half-Year 2017 Results

  9/14/2017